SCHEMBL468046

SCHEMBL468046

Clc1ccc(-c2nccs2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.63
LOXL2 Q9Y4K0 1/20 0.60
ADRB2 P07550 2/20 0.55
HSD11B1 P28845 1/20 0.50
CYP2A6 P11509 1/20 0.50
CYP1A1 P04798 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP1B1 Q16678 1/20 0.49
FBP1 P09467 1/20 0.47
KDM4E B2RXH2 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
RAB9A P51151 2/20 0.46
LMNA P02545 2/20 0.46
MGAM O43451 3/20 0.44
GAA P10253 3/20 0.44
SI P14410 3/20 0.44
MGAM2 Q2M2H8 3/20 0.44
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
CYP19A1 P11511 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722198 0.89 PDPK1 (0.77) PDPK1LOXL2ADRB2CYP2A6RAB9A
Acetic Acid SCHEMBL9382210 0.88 PDPK1 (0.55) PDPK1LOXL2ADRB2HSD11B1CYP1A2
SCHEMBL28033040 0.85 PDPK1 (0.56) PDPK1LOXL2ADRB2HSD11B1CYP2A6
SCHEMBL28487238 0.81 PDPK1 (0.52) PDPK1LOXL2ADRB2HSD11B1CYP2A6
SCHEMBL17704291 0.80 PDPK1 (0.65) PDPK1LOXL2ADRB2CYP2A6RAB9A
SCHEMBL31051067 0.79 KMT2A (0.42) PDPK1LOXL2ADRB2HSD11B1KDM4E
SCHEMBL1439923 0.79 LOXL2 (0.67) PDPK1LOXL2ADRB2CYP2A6RAB9A
SCHEMBL28842595 0.79 LOXL2 (0.67) PDPK1LOXL2ADRB2CYP2A6RAB9A
SCHEMBL19219079 0.78 PDPK1 (0.63) PDPK1LOXL2ADRB2CYP2A6KDM4E
SCHEMBL466426 0.78 PDPK1 (0.63) PDPK1LOXL2ADRB2CYP2A6FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230390259-A1 PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-12-07 US claimed
CN-109912626-B Thiazolotriazole superoxide dismutase agonist and preparation method and application thereof 浙江瑀美生物科技有限公司 2021-07-23 CN claimed
US-20210085658-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDONE DERIVATIVES SK BIOPHARMACEUTICALS CO., LTD. 2021-03-25 US claimed
EP-3394054-B1 NOVEL 1,2,3 TRIAZOLE-THIAZOLE COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF COUNCIL SCIENT IND RES (IN) 2019-11-06 EP claimed
US-10456385-B2 Pharmaceutical composition comprising pyridone derivatives SK BIOPHARMACEUTICALS CO., LTD. (KR) 2019-10-29 US claimed
CN-109912626-A A kind of thiazole and triazole superoxide dismutase agonist and its preparation method and application 河南湾流生物科技有限公司 2019-06-21 CN claimed
US-20180263965-A1 PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES SK BIOPHARMACEUTICALS CO LTD (KR) 2018-09-20 US claimed
US-9987259-B2 Pharmaceutical composition comprising pyridone derivatives SK BIOPHARMACEUTICALS CO., LTD. (KR) 2018-06-05 US claimed
US-20160166552-A1 PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES SK BIOPHARMACEUTICALS CO LTD (KR) 2016-06-16 US claimed
US-9271976-B2 Pharmaceutical composition comprising pyridone derivatives SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-03-01 US claimed
WO-2011056503-A1 AZABICYCLO[2.2.1] HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-12 WO claimed
WO-2011056573-A1 AZABICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-12 WO claimed
EP-2271650-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS Bristol-Myers Squibb Company (US) 2011-01-12 EP claimed
US-7863291-B2 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2011-01-04 US claimed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 US claimed
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY 2009-10-29 US claimed
WO-2009131926-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-29 WO claimed
WO-1992012130-A1 PIPERIDINE DERIVATIVES SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 1992-07-23 WO claimed
EP-0494717-A1 Piperidine derivatives SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1992-07-15 EP claimed
US-4259336-A ANALGESIC, ANTIPYRETIC, ANTITHROMBOTIC, ANTIPHLOGISTIC BOEHRINGER INGELHEIM GMBH (DE) 1981-03-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 PDPK1 1859/4885LOXL2 4093/4885ADRB2 91/4885
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA6 PDPK1 1859/4885LOXL2 4093/4885ADRB2 91/4885
US-20180263965-A1 PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES PLPBP, PDXK, PIR PDPK1 426/4885LOXL2 3726/4885ADRB2 544/4885
US-20230390259-A1 PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES PLPBP, PDXK, PIR PDPK1 426/4885LOXL2 3726/4885ADRB2 544/4885
US-20160166552-A1 PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES PLPBP, PDXK, PIR PDPK1 426/4885LOXL2 3726/4885ADRB2 544/4885
US-10456385-B2 Pharmaceutical composition comprising pyridone derivatives PLPBP, PDXK, PIR PDPK1 426/4885LOXL2 3726/4885ADRB2 544/4885
US-20210085658-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDONE DERIVATIVES PLPBP, PDXK, PNPO PDPK1 426/4885LOXL2 3669/4885ADRB2 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.